Search

Your search keyword '"Sundaram, Murali"' showing total 1,393 results
Start Over Author "Sundaram, Murali"
1,393 results on '"Sundaram, Murali"'

16. An Imaging Approach to Bone Tumors

Author

Holden, Darlene M., Ilaslan, Hakan, Sundaram, Murali, Santini-Araujo, Eduardo, editor, Kalil, Ricardo K., editor, Bertoni, Franco, editor, and Park, Yong-Koo, editor

Published
2020
Full Text
View/download PDF

21. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial

Author

Scheinfeld, Noah, Sundaram, Murali, Teixeira, Henrique, Gu, Yihua, and Okun, Martin

Subjects
hidradenitis suppurativa, pain, depression, adalimumab, tumor necrosis factor α, quality of life
Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease with frequent comorbidities of painand depression. Adalimumab treatment for 16 weeks improved HS lesions significantly versus placebo (NCT00918255).Objective: The relationship between pain and depressive symptoms and the effects of adalimumab on each was examined in this post hoc analysis.Methods: Patients with moderate to severe HS (N=154) were randomized 1:1:1 to adalimumab 40 mg weekly (ew), adalimumab 40 mg every other week (eow), or placebo. Skin pain was assessed using a visual analog scale (VAS; 0–100 mm). Depressive symptoms were assessed using the 9-item Patient Health Questionnaire (PHQ-9; score ≥10 indicative of depression).Results: At baseline, overall mean±SD pain VAS was 54.3±26.5 mm and 41.8% of patients had PHQ-9 scores ≥10. At baseline, VAS pain scores (mean±SD) were significantly higher (P

Published
2016

23. Efficacy, Effectiveness, and Safety of Interventions for Von Hippel-Lindau Associated Renal Cell Carcinoma: A Systematic Literature Review

Author

Jonasch, Eric, Balijepalli, Chakrapani, Yan, Kevin, Gullapalli, Lakshmi, Li, Joyce, and Sundaram, Murali

Abstract

Background: A small proportion of renal cell carcinoma (RCC) are associated with hereditary syndromes such as von Hippel-Lindau disease (VHL) and are commonly treated with surgical interventions. More recently, systemic treatments for VHL-associated RCC have been assessed as an alternative to surgery.Methods: A systematic literature review was conducted by searching MEDLINE, EMBASE, and Cochrane Registry of Controlled Trials to collect and interpret published evidence on treatments for VHL-associated RCC patients to better understand the treatment landscape.Results: This review identified 32 primary studies, comprised of single-arm clinical trials and real-world studies assessing systemic, surgical, radiological, or image guided ablation interventions. In clinical trials, treatment with sunitinib and pazopanib showed an objective response in 33% and 52% of RCC lesions respectively. For patients treated with belzutifan, 64% of patients showed an objective response, of which 7% were complete response and 57% were partial responses with a 24-month PFS rate of 96%. In real-world studies, treatment with sunitinib, pazopanib, axitinib, and sorafenib showed an objective response in 40%, 0%, 33%, and 25% of RCC lesions respectively, and all the responses were partial. In the studies assessing surgical, radiological, or image guided ablation interventions primary failure/re-intervention rates ranged from 2% to 84%.Conclusion: Local procedures are still a mainstay in the management of patients with non-metastatic VHL-associated RCC although multiple procedures incur an increasing rate of complications. A limited number of clinical trials and real-world studies evaluated VEGF-TKIs for the treatment of VHL-RCC, while responses were observed, long term treatment was limited by toxicities.

Published
2024
Full Text
View/download PDF

27. Primary bone tumours

Author

Murphy, Jennifer N, primary, James, Steven L J, additional, Sundaram, Murali, additional, and Davies, A Mark, additional

Published
2020
Full Text
View/download PDF

32. Anemias

Author

Ilaslan, Hakan, Sundaram, Murali, Ilaslan, Hakan, and Sundaram, Murali

Published
2016
Full Text
View/download PDF

44. Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups.

Author

Karam, Jose A., Bhattacharya, Rituparna, Ogbomo, Adesuwa, Gautam, Santosh, Yu, Rebekah, Sundaram, Murali, Imai, Kentaro, Chhabra, Jatin, and Haas, Naomi B.

Subjects
RENAL cell carcinoma, NEPHRECTOMY, OVERALL survival, PROGRESSION-free survival, SURVIVAL rate
Abstract

Objectives: To examine real‐world characteristics, journey, and outcomes among patients with locoregional, nonmetastatic renal cell carcinoma (RCC). Methods: A retrospective analysis of medical records from the ConcertAI Oncology Dataset was performed on adults in the United States with newly diagnosed nonmetastatic RCC between January 2012–December 2017 who received surgical treatment, and were followed until August 2021. Patients were stratified based on the risk of recurrence after nephrectomy. Recurrence rate and survival outcomes were assessed. Results: The cohort (n = 439) had a median age of 64 years, 66.1% were male, and 76.5% had clear‐cell histology. The median follow‐up time from nephrectomy was 39.3 months overall, 41.0 months for intermediate‐high‐risk patients (n = 377; 85.9%) and 24.1 months for high‐risk patients (n = 62; 14.1%). For intermediate‐high‐ and high‐risk patients, respectively, 68.4% and 56.5% had ≥1 medical oncologist visit after nephrectomy. Of 260 patients with documentation of postoperative imaging assessments, 72% were ordered by medical oncologists, and the median time from initial nephrectomy to the first scan was 110 days (intermediate‐high‐risk) and 51 days (high‐risk). Provider‐documented recurrence occurred in 223 (50.8%) patients, of whom 41.7% had ≥1 medical oncologist visit before the recurrence. Three‐year disease‐free survival (DFS), and overall survival rates were 49.4% and 80.8% (all patients): 27.7% and 64.7% (high‐risk); and 52.9% and 83.3% (intermediate‐high‐risk). Conclusions: Our study reports low DFS after nephrectomy for patients with intermediate‐high‐ and high‐risk RCC. Subsequent approval and use of new and newly approved adjuvant therapeutic options could potentially delay or prevent recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results